Terms: = Prostate cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
186 results:
1. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract] [Full Text] [Related]
2. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
3. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
[TBL] [Abstract] [Full Text] [Related]
4. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
[TBL] [Abstract] [Full Text] [Related]
5. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ; Kozin SV; Matsui A; Goldberg SI; Aoki S; Shigeta K; Mamessier E; Smith MR; Michaelson MD; Lee RJ; Duda DG
Radiother Oncol; 2024 Mar; 192():110091. PubMed ID: 38224917
[TBL] [Abstract] [Full Text] [Related]
6. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
[TBL] [Abstract] [Full Text] [Related]
7. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
McNeel DG; Emamekhoo H; Eickhoff JC; Kyriakopoulos CE; Wargowski E; Tonelli TP; Johnson LE; Liu G
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101860
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis.
Noori M; Azizi S; Mahjoubfar A; Abbasi Varaki F; Fayyaz F; Mousavian AH; Bashash D; Kardoust Parizi M; Kasaeian A
Front Immunol; 2023; 14():1181051. PubMed ID: 38022569
[TBL] [Abstract] [Full Text] [Related]
9. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and Safety of Programmed Death-1 (pd-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant prostate cancer: A Systematic Review and Meta-analysis.
Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
[TBL] [Abstract] [Full Text] [Related]
11. Anti-pd-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE; Obradovic AZ; Dallos MC; Lim EA; Runcie K; Ager CR; McKiernan J; Anderson CB; Decastro GJ; Weintraub J; Virk R; Lowy I; Hu J; Chaimowitz MG; Guo XV; Zhang Y; Haffner MC; Worley J; Stein MN; Califano A; Drake CG
Cancer Cell; 2023 Nov; 41(11):1972-1988.e5. PubMed ID: 37922910
[TBL] [Abstract] [Full Text] [Related]
12. A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy.
Chen Z; Yang X; Chen Z; Li M; Wang W; Yang R; Wang Z; Ma Y; Xu Y; Ao S; Liang L; Cai C; Wang C; Deng T; Gu D; Zhou H; Zeng G
BMC Med; 2023 Oct; 21(1):402. PubMed ID: 37880708
[TBL] [Abstract] [Full Text] [Related]
13. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in prostate cancer treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract] [Full Text] [Related]
14. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-pd-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract] [Full Text] [Related]
15. Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?
Plas S; Pircher A; Heidegger I
Curr Opin Urol; 2023 Nov; 33(6):458-471. PubMed ID: 37603022
[TBL] [Abstract] [Full Text] [Related]
16. prostate cancer cells synergistically defend against CD8
Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
[TBL] [Abstract] [Full Text] [Related]
17. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6.
Chen S; Lu K; Hou Y; You Z; Shu C; Wei X; Wu T; Shi N; Zhang G; Wu J; Chen S; Zhang L; Li W; Zhang D; Ju S; Chen M; Xu B
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094986
[TBL] [Abstract] [Full Text] [Related]
18. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of prostate cancer.
Wang D; Cheng C; Chen X; Wang J; Liu K; Jing N; Xu P; Xi X; Sun Y; Ji Z; Zhao H; He Y; Zhang K; Du X; Dong B; Fang Y; Zhang P; Qian X; Xue W; Gao WQ; Zhu HH
Adv Sci (Weinh); 2023 Jun; 10(17):e2206889. PubMed ID: 37092583
[TBL] [Abstract] [Full Text] [Related]
19. HIF1α-dependent and independent pathways regulate the expression of PD-L1 in prostate cancer.
Xanthopoulou ET; Kakouratos C; Nanos C; Gkegka AG; Kalaitzis C; Giatromanolaki A; Koukourakis MI
Med Oncol; 2023 Apr; 40(5):151. PubMed ID: 37067635
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with pd1/PD-L1 immune checkpoint inhibitors plus chemotherapy.
Villacampa G; Cresta Morgado P; Navarro V; Viaplana C; Dienstmann R
Cancer Treat Rev; 2023 May; 116():102542. PubMed ID: 37003083
[TBL] [Abstract] [Full Text] [Related]
[Next]
